A folded and immunogenic IgE-hyporeactive variant of the major allergen Phl p 1 produced in Escherichia coli

BMC Biotechnology

Mats Ohlin¹  Claes von Wachenfeldt²  Harm Otten²  Mattias Levin¹ 

[1]Dept. of Immunotechnology, Lund University, Medicon Village building 406, S-223 81, Lund, Sweden

[2]Lund Protein Production Platform (LP3), Lund University, Lund, Sweden

关键词: Protein fold;    Production;    Immunogenicity;    IgE;    Hypoallergen;    Group 1 grass pollen allergen;   

Others  :  1216715
DOI  :  10.1186/s12896-015-0150-z

 received in 2014-09-02, accepted in 2015-04-22,  发布年份 2015

【 摘 要 】

Background

Group 1 grass pollen allergens are a major cause of allergic disease. Specific immunotherapy involving controlled administration of allergens can be used as a disease-modifying treatment for such disease. Recombinant allergen variants with reduced IgE binding capacity may be used as component in such vaccines, as they may induce fewer treatment side effects than materials currently in use. A mutated variant of the immunodominant C-terminal domain of the group 1 grass pollen allergen Phl p 1 was recently established through an approach that used a set of human monoclonal IgE as a guide to identify mutations that disturbed IgE-allergen interactions. Further analysis of this domain is required to establish its potential for use in treatment.

Methods

GST-tagged wild-type and mutated C-terminal domains of Phl p 1 were produced in Escherichia coli TUNER(DE3). The products were purified by affinity chromatography on immobilized glutathione. GST was removed by enzymatic cleavage and tag-free products were purified by size exclusion chromatography. Products were assessed by SDS-PAGE, circular dichroism spectroscopy, differential scanning fluorimetry and dynamic light scattering. Rats were immunized with GST-tagged and tag-free mutated C-terminal domain of Phl p 1. Antigen-binding properties of induced antibodies were assessed by immunochemical analysis.

Results

The mutated domain has a structure very similar to that of the wild-type domain as determined by circular dichroism, but a reduced thermal stability. Immunization of rats demonstrates that this IgE-hyporeactive domain, despite its three sequence modifications (K8A, N11A, D55A), is able to induce antibodies that substantially block the binding of allergic subjects’ IgE to the wild-type allergen.

Conclusions

It is concluded that this IgE-hyporeactive molecule can be produced in folded form and that it is able to induce an antibody response that efficiently competes with IgE recognition of Phl p 1. These findings suggest that it, or a further evolved variant thereof, is a candidate for use as a component in specific immunotherapy against grass pollen allergy.

【 授权许可】

   
2015 Levin et al.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol. 2008; 8:205-17.
• [2]Linhart B, Valenta R. Vaccines for allergy. Curr Opin Immunol. 2012; 24:354-60.
• [3]Valenta R, Linhart B, Swoboda I, Niederberger V. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy. 2011; 66:775-83.
• [4]Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J. 2004; 24:758-64.
• [5]Laffer S, Vrtala S, Duchêne M, van Ree R, Kraft D, Scheiner O et al.. IgE-binding capacity of recombinant timothy grass (Phleum pratense) pollen allergens. J Allergy Clin Immunol. 1994; 94:88-94.
• [6]Niederberger V, Laffer S, Fröschl R, Kraft D, Rumpold H, Kapiotis S et al.. IgE antibodies to recombinant pollen allergens (Phl p 1, Phl p 2, Phl p 5, and Bet v 2) account for a high percentage of grass pollen-specific IgE. J Allergy Clin Immunol. 1998; 101:258-64.
• [7]Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005; 116:608-13.
• [8]Flicker S, Steinberger P, Ball T, Krauth MT, Verdino P, Valent P et al.. Spatial clustering of the IgE epitopes on the major timothy grass pollen allergen Phl p 1: importance for allergenic activity. J Allergy Clin Immunol. 2006; 117:1336-43.
• [9]Levin M, Rydnert F, Källström E, Tan LW, Wormald PJ, Lindstedt M et al.. Phl p 1-specific human monoclonal IgE and design of a hypoallergenic group 1 grass pollen allergen fragment. J Immunol. 2013; 191:551-60.
• [10]Gadermaier E, Levin M, Flicker S, Ohlin M. The human IgE repertoire. Int Arch Allergy Immunol. 2014; 163:77-91.
• [11]Persson H, Karbalaei Sadegh M, Greiff L, Ohlin M. Delineating the specificity of an IgE-encoding transcriptome. J Allergy Clin Immunol. 2007; 120:1186-92.
• [12]Aalberse RC, Crameri R. IgE-binding epitopes: a reappraisal. Allergy. 2011; 66:1261-74.
• [13]Niemi M, Jylhä S, Laukkanen ML, Söderlund H, Mäkinen-Kiljunen S, Kallio JM et al.. Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen. Structure. 2007; 15:1413-21.
• [14]Padavattan S, Flicker S, Schirmer T, Madritsch C, Randow S, Reese G et al.. High-affinity IgE recognition of a conformational epitope of the major respiratory allergen Phl p 2 as revealed by X-ray crystallography. J Immunol. 2009; 182:2141-51.
• [15]Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012; 30:4328-35.
• [16]Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R. Strategies for converting allergens into hypoallergenic vaccine candidates. Methods. 2004; 32:313-20.